Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2020 08:00 ET | Source: Posit Science

Study: Combining Brain Training and Walking Helps Heart Failure Patients

SAN FRANCISCO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- A new study from Emory University found a combined therapy of brain training and aerobic exercise improved multiple measures that drive better health...
February 25, 2019 08:00 ET | Source: Posit Science

Study: Brain Training for Heart Failure

SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- A new study — made available online in advance of print by The American Journal of Geriatric Psychiatry and conducted by a team from Emory University...
October 22, 2015 02:00 ET | Source: Mesoblast

Mesoblast Chairman's Address to 2015 Annual General Meeting

NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting. This has been another exciting and productive year in the history of our...
September 29, 2015 21:10 ET | Source: Mesoblast

Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure

NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...
August 16, 2015 20:28 ET | Source: Mesoblast

Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program

NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
October 30, 2013 18:41 ET | Source: Mesoblast

FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS

NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...